|
|
Article: Third TNF-blocker targets psoriatic arthritis.(Rheumatology)(tumor necrosis factor inhibitor)
- Article from:
- Internal Medicine News
- Article date:
- December 15, 2005
- Author:
CopyrightCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MONTREAL -- A third tumor necrosis factor inhibitor has been added to the drug arsenal for treating psoriatic arthritis.
Adalimumab, a fully human, anti-TNF monoclonal antibody, significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active psoriatic arthritis, according to the findings of a multicenter study.
Adalimumab and infliximab have been approved by the Food and Drug Administration for the treatment of psoriatic arthritis (PsA), but not for the dermatologic treatment of psoriasis in the absence ...